کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2533895 | 1559064 | 2010 | 7 صفحه PDF | دانلود رایگان |

Renal fibrosis is the final common pathway of chronic kidney disease, and its progression predicts the degree of renal dysfunction. We investigated the renoprotective properties of pirfenidone in a remnant kidney model of chronic renal failure to determine its pharmacological potency compared to enalapril. Five-sixths nephrectomized rats were fed diet containing pirfenidone (approximately 700 mg/kg/day) for 8 weeks. Pirfenidone steadily inhibited the progression of proteinuria, but not to a significant degree. Pirfenidone prevented the elevation of plasma creatinine and blood urea nitrogen. At the end of the experiment, pirfenidone had reduced systolic blood pressure by means of its renoprotective effect. In a histological study, pirfenidone improved interstitial fibrosis in the renal cortex. These effects were supported by the suppression of the expression of TGF-β and fibronectin in the mRNA of the kidney. In contrast, pirfenidone had little effect on the expression of α-smooth muscle actin, which is one of the proteins responsible for epithelial–mesenchymal transition. This property was confirmed by the TGF-β-induced transdifferentiation observed in cultured normal rat kidney tubular epithelial NRK52E cells. These results suggest that pirfenidone improves the progression of chronic renal failure via its antifibrotic action, although pirfenidone has less effective TGF-β-induced epithelial to mesenchymal transdifferentiation.
Journal: European Journal of Pharmacology - Volume 629, Issues 1–3, 10 March 2010, Pages 118–124